baber/WOPTO huggingface dataset:
Patent NZ-504675-A (NZ)
Title: Techniques and systems for analyte detection
Inventor: GRUBBS ROBERT H
IPC: G01N27/22
Filed: 1998-08-07
Abstract: An integrated circuit (205) comprises a plurality of sensor sites (210) formed on the integrated circuit, and electrical terminals (710, 715) formed to couple to the sensor material at the sensor sites. Each sensor site is either a sensor wall or a sensor trench and the sensor material is constrained at the sensor site and has regions of a nonconductive organic material and a conductive material. In the presence of an analyte, the sensor material has measurable changes in an electrical property. The electrical terminals transmit electrical signals to evaluate the change in the electrical property of the sensor material.
Patent NZ-507203-A (NZ)
Title: Use of dexmedetomidine for ICU sedation
Inventor: AANTAA RIKU
IPC: C07D233/58
Filed: 1999-03-31
Abstract: Use of dexmedetomidine or a pharmaceutically acceptable salt  thereof in the manufacture of a medicament for use  in intensive  care  unit sedation and a method  of  sedating  a patient   while  in  the  intensive  care  unit   (ICU)   is disclosed.     The     method    comprises     administering dexmedetomidine   or  a  pharmaceutically  acceptable   salt thereof  to a patient in need thereof for a sufficient  time period.   Also disclosed is a method of sedating  a  patient in   the   ICU   by  administering  dexmedetomidine   or   a pharmaceutically    acceptable   salt    thereof,    wherein dexmedetomidine is the sole active agent.
Patent NZ-511068-A (NZ)
Title: Use of hyaluronic acid for preventing, reducing, and treating radiation cystitis
Inventor: POMMERVILLE PETER J
IPC: A61P13/10
Filed: 1999-10-22
Abstract: A composition comprising hyaluronic acid having an average molecular weight of not less than 2X 105 Daltons and a pharmaceutically acceptable carrier is used to prevent, reduce or treat radiation cystitis caused by radiotherapy of the bladder area.
Patent NZ-515689-A (NZ)
Title: Tape dispenser
Inventor: KELDERS JOHANNES HUBERTUS JOZE
IPC: B65H35/07
Filed: 2000-06-02
Abstract: A new tape dispenser (4) is proposed, with a two-piece horizontally segmented housing (3), a holder for a roll of tape, a discharge opening (8), a guide applicator (10) fitted to the housing (3) in close vicinity to the discharge opening (8), by means of which the tape can be applied onto a substrate, and a blade (15) with a cutting edge situated downstream of the guide applicator (10). The housing (3) has an elongated anatomical form which can be kept in the enclosing hand and at least a shallow upper depression in the housing is provided close to and adjacent to the guide applicator (10) in order to exert a pressure onto the guide applicator (10) by the index finger.
Patent NZ-517635-A (NZ)
Title: New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
Inventor: GRAMS FRANK
IPC: C07D403/04
Filed: 2000-09-29
Abstract: Compounds of formula (I), wherein: R1 is phenoxy, optionally substituted by halogen, hydroxy, alkoxy, alkyl, cyano or nitro groups, R2 is pyrimidine, pyrazine or its N-oxides, or phenyl substituted by -SO2NR3R4, R3 and R4 independently are H, alkyl optionally substituted by OH, H(CH3)2, or interrupted by oxygen, or represent COR5 wherein R5 is alkyl optionally substituted by NH2. The compounds are used in the manufacture of medicaments having metallo-proteinase inhibitor activity.
Patent NZ-520241-A (NZ)
Title: Adenosine receptor modulators
Inventor: BORRONI EDILIO MAURIZIO
IPC: C07D495/04
Filed: 2001-02-15
Abstract: Described is the use of compounds of formula II, III, or IV for the manufacture of medicaments for the control or treatment of Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure, substance abuse, sedation, and for use as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents; for which the substituents are defined herein.
Patent NZ-521639-A (NZ)
Title: Carbamate caspase inhibitors and uses thereof
Inventor: BEBBINGTON DAVID
IPC: C07D403/12
Filed: 2001-03-29
Abstract: Described is the use of compounds of formula I in the manufacture of medicaments for treating diseases alleviated by treatment with a caspase inhibitor, wherein Z is oxygen or sulfur and the remaining substituents are defined herein.
Patent NZ-523553-A (NZ)
Title: Thrombin inhibitors comprising an aminoisoquinoline group
Inventor: REWINKEL JOHANNES BERNARDUS MA
IPC: C07D217/22
Filed: 2001-07-09
Abstract: A compound of formula (I) and its a pharmaceutically acceptable salt is disclosed, wherein: R1 is cyclopentyl, cyclohexil or branched (3-4C) alkyl; R2 is cyclohexyl or phenyl; R3 is H or methyl; and A is an unsubstituted saturated 4, 5 or 6-membered ring; or thereof. The compounds of formula (I) have anticoagulant activity and can be used in treating or preventing thrombin-mediated and thrombin-associated diseases.
Patent NZ-524081-A (NZ)
Title: Dispenser
Inventor: BACON RAYMOND JOHN
IPC: A61M15/00
Filed: 2001-07-24
Abstract: A dispenser for a gaseous, gas borne or droplet substance contained in a source thereof, the dispenser including: a body (1) with a mouthpiece; (2) a junction member in the body for the substance source; and a breath actuable valve, (8) for controlling the release of the gas or liquid containing or comprising the substance, the valve comprising: a flexible tube for receiving the said gas or liquid, the tube extending from a valve inlet connected to the junction member and having a portion (21) which is kinkable for closure of the valve and movable to an open position in which the tube is un-kinked for opening of the valve; and a member arranged for movement in the body by inhalation to un-kink the valve; the tube being kinked to an obturating extent when the movable member is in a ready position and un-kinked when the movable member is moved on inhalation for release of the gas or liquid; wherein: the movable member is or includes a flap (7) arranged in the body for action of breath on it on inhalation; the junction member,the flexible tube and the movable flap are a single injection moulding of plastics material; and the movable flap is pivotally connected to the junction member.
Patent NZ-524388-A (NZ)
Title: Tube-forming unit for a form-fill-seal machine with anvil isolated from folding box to isolate vibrations
Inventor: COSARO LINO
IPC: B29C53/50
Filed: 2003-02-25
Abstract: A form-fill-seal machine has an ultrasonic vibration emitter head 11 positioned outside the tube being formed by the overlapping of the margins 3 and 5 of a film web and an anvil 13 positioned inside the tube defined by those margins 3 and 5, the anvil being mounted on a mount 25 which is supported by a frame element entirely independent of the forming box 1 used to suitably fold the film, so as to isolate the anvil from vibrations sustained from the forming box. The anvil mount 25 may be mounted directly to a carrier body for the ultrasonic vibration emitter and has the shape of an inverted letter J where the anvil 13 is positioned near the toe 25a of the J, the mounting to the sealing machine frame is at the top of the stem 25c of the J and there is a slot 25b between the toe 25a and the stem 25c.
Patent NZ-526502-A (NZ)
Title: Decontamination of animal feed containing prion (eg. BSE agent)
Inventor: KEMP PHILIP WILLIAM
IPC: A23K1/10
Filed: 2001-11-14
Abstract: Disclosed are methods of manufacturing animal feeds or fodder from animal material comprising adding alkali to the material to maintain a pH of at least 8.5, heating the material to a temperature ranging from 60-99 degrees c, then dehydrating the material obtained. Such methods are useful for reducing prion contamination, particular where the animal material has the potential to carry prion relating to Transmittable Degenerative Encephalopathies ( TDE ), such as BSE or mad cow disease , scrapie , CJD , GSS and Kuru . Feeds produced by such methods are also disclosed.
Patent NZ-526971-A (NZ)
Title: Stabilized spinel battery cathode material and methods
Inventor: HOWARD WILMONT F
IPC: C01G45/00
Filed: 2002-01-18
Abstract: Improved stabilized spinel battery cathode material and methods of treating particles of spinel battery cathode material to produce a protective coating of battery-inactive lithium metal oxide on the particles are provided. The methods basically comprise mixing the spinel particles with a particulate reactant selected from a lithium salt, a lithium metal oxide or a mixture of a lithium salt and a metal oxide and then heating the resultant particulate mixture for a time and temperature to react the particulate reactant with the spinel particles whereby a protective coating of lithium metal oxide is formed on the spinel particles and the lithium content of the spinel adjacent to the coating is increased a limited amount.
Patent NZ-534294-A (NZ)
Title: Installation for treating water by means of flotation
Inventor: VION PATRICK
IPC: C02F1/24
Filed: 2002-12-11
Abstract: A water purification installation includes a coagulation area, a flocculation area, an area for mixing, in an upflow, the flocculated water with pressurised water which is delivered by a microbubble-generating pressurisation-pressure reduction system, and a flotation area. Suspended matter, which is brought to the surface by the microbubbles, is evacuated from the upper part of the flotation area. Moreover, the lower part of said flotation area includes means of collecting the clarified water. The geometry of the flotation area is such that the ratio between the height (H) of the area located above the clarified water collection means and the length (L) of the area is between 0.3 and 1; and the ratio between the surface (Sa) of the nappe at the outlet of the mixing area and the surface (Sp) of the actual flotation area is between 0.05 and 0.5 and, preferably, between 0.1 and 0.35.
Patent NZ-535076-A (NZ)
Title: Moisture and density detector (MDD)
Inventor: STEELE PHILIP H
IPC: G01N9/24
Filed: 2003-02-04
Abstract: A device for measuring the density and moisture content of dielectric materials, with particular application to lumber, is disclosed. The device passes a radio frequency signal 105 of up to 1000 MHz between two adjacent or opposed electrodes 110, 120 and measures 160 the signal strength and phase shift of the received signal. The output signal is compared to predetermined values 180 to give an estimate of moisture content and density of the sample 130.
Patent NZ-535121-A (NZ)
Title: NK1 antagonists
Inventor: WROBLESKI MICHELLE LACI
IPC: A61P25/20
Filed: 2003-03-12
Abstract: Disclosed is a compound of formula (I) wherein the substituents are as described in the specification. Compounds of the type disclosed are NK1 antagonists and are useful for treating a physiological disorder, symptom or disease in a patient in need of such treatment, wherein said physiological disorder, symptom or disease is a respiratory disease, depression, anxiety, phobia, bipolar disorder, alcohol dependence, psychoactive substance abuse, nociception, psychosis, schizophrenia, stress related disorder, obsessive/compulsive disorder, bulemia, anorexia nervosa, binge eating, sleep disorder, mania, premenstrual syndrome, gastrointestinal disorder, obesity, headache, neuropathic pain, post-operative pain, chronic pain syndrome, bladder disorder, genitourinary disorder, cough, emesis or nausea.
Patent NZ-539405-A (NZ)
Title: Analgesic comprising a high-ibuprophen content wherein the sodium salt is used and the water content is between 8 and 16 percent
Inventor: GRUBER PETER
IPC: A61K9/20
Filed: 2003-10-09
Abstract: A non effervescent tablet of ibuprofen, comprising a tablet core and, if desired, a-sugar or film coat, wherein the tablet core, based on the weight of the tablet core, consists of 50 to 100% by weight sodium ibuprofen hydrate and 0 to 50% by weight auxiliary material component and contains no lubricant and no disintegrant, and wherein the sodium ibuprofen hydrate has a water content of 8 to 16% by weight possesses a sufficient hardness, is comparably small and leads to a particularly rapid increase in blood level and thereby to an accelerated onset of analgesic effect. Contrary to the current doctrine sodium ibuprofen hydrate having suitable water content is sufficiently compressible. Fig. 3 shows the dissolution profile of film tablets in 0.1 M hydrochloric acid (pH 1.2) according to the Paddle Method at 100 rpm in comparison to a Dolormin film tablet and a Nurofen film tablet.
Patent NZ-539475-A (NZ)
Title: Wrapping material
Inventor: HOWELL OWEN TORRIDON
IPC: B65B23/00
Filed: 2003-03-28
Abstract: An extruded multi-layer protective film product comprises: at least one first layer of plastic bubble sheet having a first face and a second face; at least one second layer of non-woven synthetic fabric material over the first face of the bubble sheet; a further layer formed over the second face of the bubble sheet wherein the further layer is formed of a different material to that of the second layer. (62) Divided out of 525041
Patent NZ-543309-A (NZ)
Title: Multiplex screening for lysosomal storage disorders (LSDs)
Inventor: MEIKLE PETER JOHN
IPC: G01N33/543
Filed: 2004-03-31
Abstract: Provided is a protein profiling method for diagnosing pre-clinical status, or clinical status and determining therapy of a lysosomal storage disorder (LSD), comprising determining quantity of LAMP-1 and saposin C, calculating target proportion between LAMP-1 and saposin C and comparing it to reference proportion from reference samples obtained from animals having known LSD preclinical or clinical status after adjustment and comparing the adjusted target quantities to find a significant deviation of target from reference based on Mann-Whitney U test, wherein the quantities of LAMP-1 and saposin C are determined by a capture antibody conjugated to a microsphere. Further provided are variants of the method using other sugar metabolism enzymes, like alpha galactosidase, glucocereborosidase etc.
Patent NZ-546394-A (NZ)
Title: Aminopyridine derivatives as inductible NO-synthase inhibitors
Inventor: FUCHSS THOMAS
IPC: A61P29/00
Filed: 2004-09-30
Abstract: Disclosed is a compound of formula (I), or a salt, N-oxide, or salt of an N-oxide thereof, wherein R1 is H or 1-4C-alkyl, R4 is 1-4C-alkyl or 1-4C-alkoxy, and wherein the other substituents are as described in the specification. Also disclosed is the use of the compound to treat acute inflammatory diseases, including chronic inflammatory diseases of peripheral organs and the CNS.
Patent NZ-548181-A (NZ)
Title: Diazabicyclo[3.2.2]nonane derivatives as cholinergic receptor modulators and nicotinic acetylcholine receptor ligands
Inventor: PETERS DAN
IPC: A61K31/439
Filed: 2005-02-01
Abstract: Disclosed are diaza-bicyclo[3.2.2]nonane derivatives represented by Formula IV which are useful for the treatment, prevention or alleviation of conditions which are responsive to modulation of cholinergic receptors, wherein n is 2; L represents a single (covalent) bond; A' represents a furanyl, oxazolyl, oxadiazolyl, thiazolyl or pyridazinyl group; A" represents a phenyl group; and R' represents hydrogen, alkyl or -(C=O)-NH-B'; R" represents hydrogen, alkyl , phenyl or benzyl; V represents O, S or NH; and B' represents alkyl, phenyl, benzyl or pyridyl; which phenyl, benzyl and pyridyl groups are optionally substituted one or two times with substituents selected from the group consisting of hydroxy, alkoxy, halo, trifluoromethyl, nitro, amino, alkyl-carbonyl-amino, N-alkyl-amino-carbonyl-amino (N-alkyl-ureido), N,N-dialkyl-aminocarbonyl-amino (N,N-dialkyl-ureido) and sutfamoyl.
Patent NZ-548556-A (NZ)
Title: Antidiabetic oxazolidinediones and thiazolidinediones as agonists or partial agonists of PPAR gamma
Inventor: SHI GUO Q
IPC: C07D277/34
Filed: 2005-01-18
Abstract: Disclosed is a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: A is O or S; X is a bond or CH2; R1 is selected from the group consisting of H and C1-C3 alkyl, wherein C1-C3 alkyl is optionally substituted with 1-3 F; Each R2 is independently selected from the group consisting of F, Cl, CH3, CF3, -OCH3, and -OCF3; Each R4 is independently selected from the group consisting of halogen, C1-C3 alkyl, -OC1-C3 alkyl, -OC(=O)C1-C3 alkyl, and -S(O)qC1-C3 alkyl, wherein C1-C3 alkyl, -OC1-C3 alkyl, -OC(=O)C1-C3 alkyl, and -S(O)qC1-C3 alkyl are optionally substituted with 1-3 F; Each R5 is independently selected from the group consisting of F, Cl, CH3, -OCH3, CF3, and -OCF3; R6 is selected from the group consisting of C2-C5 alkyl, -CH2Cyclopropyl, and -C(=O)C1-C3 alkyl, wherein said R6 substituent is optionally substituted with 1-3 F; m is 0 or 1; n is an integer from 1-3; P is an integer from 0-2; and q is an integer from 0-2. Also disclosed is a pharmaceutical composition comprising of the said compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and additionally, the use of the said compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of Type 2 diabetes is also disclosed.
Patent NZ-549552-A (NZ)
Title: Combination therapy involving 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (AZD2171) and a platinum anti-tumour agent
Inventor: WEDGE STEPHEN ROBERT
IPC: A61K33/243
Filed: 2005-03-22
Abstract: Disclosed is the use of AZD2171 (4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline) or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a platinum anti-tumour agent (such as cisplatin, carboplatin or oxaliplatin) in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human. Also disclosed is the use of the above combination in the manufacture of a medicament for use in the production of an anti-cancer effect (including an anti-tumour effect) in a warm-blooded animal such as a human. In addition, a pharmaceutical composition which comprises AZD2171, or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a platinum anti-tumour agent, in association with a pharmaceutically acceptable excipient or carrier is also disclosed, as is a kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and a platinum anti-tumour agent.
Patent NZ-550726-A (NZ)
Title: Bio-degradable paper board
Inventor: HSI-CHING CHANG
Filed: 2006-10-24
Abstract: A biodegradable paper board is disclosed. The paper board 10 comes in the form of a roll and has a biodegradable layer 20 coated to the paper board by an extrusion coating machine. The paper roll is pre-heated and treated by corona treatment before the biodegradable layer is applied. The biodegradable layer can be made of Polyactic Acid (PLA), Polyethylene Terephthalate (PET), or Corn Starch, which is heated to liquid form and extruded by a T-Die to be a foam-type layer which is then pressed between silicone rollers and cooling rollers to evenly press the layer on to the paper board. Both paper board and biodegradable layer are then treated by another corona treatment to define orifices in the paper board, the paper board being cut and folded to be food containers.
Patent NZ-554726-A (NZ)
Title: A foam cushion molding system and method
Inventor: SPERRY CHARLES R
Filed: 2007-04-24
Abstract: A molding system for foam-in-bag cushions comprises a mold defining a mold cavity, an air plenum separate from the mold cavity, a plurality of air passages that connect the mold cavity to the air plenum, and at least one port connected to the air plenum. The mold cavity has an open side and the mold includes a door that is movable between a closed position closing the open side of the mold cavity and an open position allowing a cushion to enter and exit through the open side. The system further comprises a pneumatic vacuum/blowout system connected with the at least one port. The vacuum/blowout system comprises a vacuum source, an air tank containing pressurized air, and a vacuum/blowout valve structured and arranged to alternately couple the at least one port either to the vacuum source or to the air tank.
Patent NZ-555320-A (NZ)
Title: Substituted piperazines as CB1 antagonists
Inventor: GILBERT ERIC J
IPC: A61K31/495
Filed: 2005-12-01
Abstract: Disclosed is a pyridine compound of Formula (I) wherein Ar1 and Ar2 are aryl or heteroaryl; and wherein the rest of the substituents are disclosed within the specification. Also disclosed is the use of a compound in the manufacture of a medicament for treating a condition or disease selected from metabolic syndrome, obesity, waist circumference, lipid profile, insulin sensitivity, neuroinflammatory disorders, cognitive disorders, psychosis, addictive behaviour, gastrointestinal disorders, and cardiovascular conditions.
Patent NZ-556021-A (NZ)
Title: Device for preparing a drink from a capsule by injection of a pressurized fluid and capsule-holder adapted therefore
Inventor: MANDRALIS ZENON IOANNIS
IPC: A47J31/06
Filed: 2006-02-03
Abstract: Device for preparation of a drink from a food substance contained in a capsule (6) comprising a fluid supply unit (5) comprising fluid supply means; a capsule holder (4) configured to receive a capsule (6). The capsule holder is removable from the fluid supply unit and can comprise a fluid injector (via inlet 77) for inserting fluid into the capsule.
Patent NZ-561362-A (NZ)
Title: Abuse-resistant retortable packaging film having oxygen barrier layer containing blend of amorphous polyamide and semicrystalline polyamide
Inventor: BEKELE SOLOMON
IPC: B32B27/34
Filed: 2006-03-16
Abstract: Disclosed is a process of preparing a retorted packaged product, comprising: (A) placing a product in a packaging article comprising a multilayer packaging film heat sealed to itself, the multilayer packaging film having a total free shrink of less than 10 percent at 185 degrees F, the multilayer packaging film comprising: (1) a crosslinked first outer layer which serves as a seal layer and product contact layer, and (2) a crosslinked O2-barrier layer comprising a blend of: (i) from 50 to 95 weight percent, based on blend weight, of polyamide-6I/6T; and (ii) a semi-crystalline polyamide comprising at least one member selected from (a) from 5 to 50 percent, based on blend weight, of PA-MXD,6/MXD,I; and (b) from 5 to 15 percent, based on blend weight, of a nucleated or non-nucleated polyamide having a viscosity number of 150 milliliters per gram to 245 milliliters per gram as measured in accordance with ISO Test Method 307; (B) sealing the article closed so that the product is surrounded by the multilayer packaging film; and (C) heating the packaged product to a temperature of at least 212 degrees for a period of at least half an hour, in the presence of pressurized steam.
Patent NZ-561927-A (NZ)
Title: Elevator system with safety device on elevator doors
Inventor: KOCHER HANS
Filed: 2007-09-25
Abstract: In an elevator system that has an elevator hoistway, a plurality of hoistway doors arranged above each other each with at least one horizontally moveable hoistway door panel, and an elevator car with a car door that has at least one horizontally movable car door panel, fastened to the car door panel is a vertically extending barrier rail. In each of the areas lying in the vertical direction between the hoistway door panels of adjacent hoistway doors two locationally fixed stopping dogs that are vertically spaced from each other are arranged so that in each case one of the stopping dogs limits the opening movement of the barrier rail, and thereby of the car door panel, when the position of the elevator car deviates in the upward direction or in the downward direction by a certain minimum distance from the intended stopping position.